查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424963

移植診斷的全球市場：按技術、提供的內容、移植類型、應用和最終用戶劃分的市場規模和份額分析 - 工業需求預測（截至 2030 年）

Transplant Diagnostics Market Size and Share Analysis by Technology, Offering, Transplant Type, Application, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 340 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年全球移植診斷市場價值將達到46.867億美元，到2029年底成長率為7.5%，到2030年將達到77.135億美元。

這是由於器官替代手術的需求不斷增加、器官替代手術前診斷程序的需求不斷增加以及傳染病的增加。

此外，晚期器官衰竭的患者數量正在增加，器官移植手術的進步使許多患者能夠接受這些手術。

從技術角度來看，分子檢測將在 2023 年以 65% 的份額引領產業，並且預計將繼續佔據主導地位。

這是因為分子檢測廣泛應用於術前診斷過程中，以測試受者和供者的相容性。 與非分子檢測相比，這些檢測方法之所以獲得認可，主要是因為它們具有技術優勢，例如可以研究大量樣品、即時分析以及較高的程序有效性。

軟體和服務業預計未來成長最快。 這是因為在競爭激烈的市場中各公司定期提供軟體更新和全面的服務。

此外，隨著更先進設備的擴展，對技術人員如何處理和使用設備的培訓課程的需求正在迅速增加。 這些因素正在推動產業的發展。

到2023年，診斷藥物類別將佔據移植診斷市場70%的份額，而這一趨勢預計將持續下去。 這是因為這種疾病的發生率正在增加。

此外，診斷類別分為移植前診斷和移植後診斷。 此外，在移植過程中，所有相關的診斷測試均在移植前進行，以確認移植物的適用性。 例子包括血液分析、組織相容性測試和傳染病測試。

到 2023 年，北美將佔據最大份額，達到 50%，而這一趨勢預計將持續下去。 這與最先進的技術和分析工具的高接受率、高昂的醫療成本、熟練的專業人員的可用性以及軟組織移植、幹細胞治療和個人化藥物的廣泛使用有很大關係。

此外，器官移植數量的增加、移植意識的提高、傳染病患者病率的增加以及更容易患慢性病的老年人口的增加推動了該行業的發展。

本報告分析了全球移植診斷市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、按地區和主要國家的市場規模前景（以貨幣形式計算） （2017-2030），我們正在按技術、供應內容、連接埠類型、應用程式和最終用戶、市場競爭現狀以及主要公司概況來調查詳細趨勢。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

  • 市場動態
    • 趨勢
    • 促進因素
    • 抑制因素/挑戰
    • 促進/抑制因子影響分析
  • 新型冠狀病毒感染 (COVID-19) 的影響
  • 波特五力分析

第六章世界市場

  • 摘要
  • 市場收入：依技術劃分（2017-2030 年）
    • 按類型劃分的分子檢測市場收入（2017-2030 年）
    • 按類型劃分的非分子檢測市場收入（2017-2030 年）
  • 市場收入：依產品劃分（2017-2030 年）
  • 市場收入：依移植類型分類（2017-2030 年）
    • 實體器官市場收入：按類型劃分（2017-2030 年）
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：按地區劃分（2017-2030 年）

第七章北美市場

  • 摘要
  • 市場收入：依技術劃分（2017-2030 年）
    • 按類型劃分的分子檢測市場收入（2017-2030 年）
    • 按類型劃分的非分子檢測市場收入（2017-2030 年）
  • 市場收入：依產品劃分（2017-2030 年）
  • 市場收入：依移植類型分類（2017-2030 年）
    • 實體器官市場收入：按類型劃分（2017-2030 年）
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第 11 章中東與非洲 (MEA) 市場

第12章美國市場

  • 摘要
  • 市場收入：依技術劃分（2017-2030 年）
    • 按類型劃分的分子檢測市場收入（2017-2030 年）
    • 按類型劃分的非分子檢測市場收入（2017-2030 年）
  • 市場收入：依產品劃分（2017-2030 年）
  • 市場收入：依移植類型分類（2017-2030 年）
    • 實體器官市場收入：按類型劃分（2017-2030 年）
  • 市場收入：依應用分類（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

  • 市場參與者及其提供的產品/服務列表
  • 主要公司的競爭基準
  • 各大公司的產品基準
  • 近期策略發展狀況

第30章公司簡介

  • bioMerieux S.A.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Hologic Inc.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings
  • BAG Diagnostics GmbH
  • Illumina Inc.

第31章附錄

簡介目錄
Product Code: 11958

The transplant diagnostics market was valued at USD 4,686.7 million in 2023, and it will grow at a rate of 7.5% by the end of this decade, to touch USD 7,713.5 million by 2030.

This is attributable to the growing requirement for organ replacement procedures, the growing requirement for diagnostic procedures before organ replacement, and the powering occurrence of communicable diseases.

Also, the number of people with final-stage organ failure is on the rise, and because of the development in organ transplantation procedures, a high number of patients can now access these surgeries.

On the basis of technology, molecular assay led the industry with a share, of 65%, in 2023, and it will continue to dominate in the future as well.

This is due to the fact that molecular assays are extensively used in presurgical diagnostic processes for testing the compatibility of a recipient and donor. These assays are mostly accepted because of their tech benefits as opposed to non-molecular assays, for example the study of numerous samples and instantaneous analysis and high procedural efficacy.

The software & services category will grow the fastest in the future. This is because of the regular updates in software and enhanced services provided by the market players remain in the competition.

Furthermore, the expansion of more progressive instruments has led to a surge in the demand for training sessions to teach technical employees to handle and use an instrument. These factors led to the evolution of the industry.

The diagnostics category dominated the transplant diagnostics market, with a share of 70%, in 2023, and it will continue like this in the future. This is credited to the increasing occurrence of ailments.

Furthermore, the diagnostic category is divided into pre-transplantation and post-transplantation diagnostic. Additionally, for transplant processes, all relative diagnostic tests will be done prior to the transplant to see the compatibility of the transplant for example blood profiling, histocompatibility testing, and communicable disease testing.

North America had the largest share, of 50%, in 2023, and it will continue like this in the future. This has a lot to do with the high acceptance rate of cutting-edge techniques and analytic tools, high healthcare spending, the obtainability of skilled experts, and the extensive use of soft tissue transplants, stem cell therapies, and tailored medications.

Furthermore, the growing count of organ replacements, the increasing consciousness of transplantation, the growing incidence of communicable ailments, and the rising elderly populace susceptible to chronic ailments are powering the industry.

There is an increasing number of organ transplants happening around the world, and this will power the demand for transplant diagnostic solutions. The trend will continue in the years to come as well.

Top Providers of Transplant Diagnostics Are:

bioMerieux S.A.

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

Abbott Laboratories

Hologic Inc.

F. Hoffmann-La Roche Ltd.

Laboratory Corporation of America Holdings

BAG Diagnostics GmbH

Illumina Inc.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by technology
    • 1.4.2. Market size breakdown, by offering
    • 1.4.3. Market size breakdown, by transplant type
    • 1.4.4. Market size breakdown, by end user
    • 1.4.5. Market size breakdown, by application
    • 1.4.6. Market size breakdown, by region
    • 1.4.7. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Technology (2017-2030)
    • 6.2.1. Molecular assay market revenue, by type (2017-2030)
    • 6.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 6.3. Market Revenue, by Offering (2017-2030)
  • 6.4. Market Revenue, by Transplant Type (2017-2030)
    • 6.4.1. Solid organ market revenue, by type (2017-2030)
  • 6.5. Market Revenue, by Application (2017-2030)
  • 6.6. Market Revenue, by End User (2017-2030)
  • 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Technology (2017-2030)
    • 7.2.1. Molecular assay market revenue, by type (2017-2030)
    • 7.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 7.3. Market Revenue, by Offering (2017-2030)
  • 7.4. Market Revenue, by Transplant Type (2017-2030)
    • 7.4.1. Solid organ market revenue, by type (2017-2030)
  • 7.5. Market Revenue, by Application (2017-2030)
  • 7.6. Market Revenue, by End User (2017-2030)
  • 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Technology (2017-2030)
    • 8.2.1. Molecular assay market revenue, by type (2017-2030)
    • 8.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 8.3. Market Revenue, by Offering (2017-2030)
  • 8.4. Market Revenue, by Transplant Type (2017-2030)
    • 8.4.1. Solid organ market revenue, by type (2017-2030)
  • 8.5. Market Revenue, by Application (2017-2030)
  • 8.6. Market Revenue, by End User (2017-2030)
  • 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Technology (2017-2030)
    • 9.2.1. Molecular assay market revenue, by type (2017-2030)
    • 9.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 9.3. Market Revenue, by Offering (2017-2030)
  • 9.4. Market Revenue, by Transplant Type (2017-2030)
    • 9.4.1. Solid organ market revenue, by type (2017-2030)
  • 9.5. Market Revenue, by Application (2017-2030)
  • 9.6. Market Revenue, by End User (2017-2030)
  • 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Technology (2017-2030)
    • 10.2.1. Molecular assay market revenue, by type (2017-2030)
    • 10.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 10.3. Market Revenue, by Offering (2017-2030)
  • 10.4. Market Revenue, by Transplant Type (2017-2030)
    • 10.4.1. Solid organ market revenue, by type (2017-2030)
  • 10.5. Market Revenue, by Application (2017-2030)
  • 10.6. Market Revenue, by End User (2017-2030)
  • 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Technology (2017-2030)
    • 11.2.1. Molecular assay market revenue, by type (2017-2030)
    • 11.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 11.3. Market Revenue, by Offering (2017-2030)
  • 11.4. Market Revenue, by Transplant Type (2017-2030)
    • 11.4.1. Solid organ market revenue, by type (2017-2030)
  • 11.5. Market Revenue, by Application (2017-2030)
  • 11.6. Market Revenue, by End User (2017-2030)
  • 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Technology (2017-2030)
    • 12.2.1. Molecular assay market revenue, by type (2017-2030)
    • 12.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 12.3. Market Revenue, by Offering (2017-2030)
  • 12.4. Market Revenue, by Transplant Type (2017-2030)
    • 12.4.1. Solid organ market revenue, by type (2017-2030)
  • 12.5. Market Revenue, by Application (2017-2030)
  • 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Technology (2017-2030)
    • 13.2.1. Molecular assay market revenue, by type (2017-2030)
    • 13.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 13.3. Market Revenue, by Offering (2017-2030)
  • 13.4. Market Revenue, by Transplant Type (2017-2030)
    • 13.4.1. Solid organ market revenue, by type (2017-2030)
  • 13.5. Market Revenue, by Application (2017-2030)
  • 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Technology (2017-2030)
    • 14.2.1. Molecular assay market revenue, by type (2017-2030)
    • 14.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 14.3. Market Revenue, by Offering (2017-2030)
  • 14.4. Market Revenue, by Transplant Type (2017-2030)
    • 14.4.1. Solid organ market revenue, by type (2017-2030)
  • 14.5. Market Revenue, by Application (2017-2030)
  • 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Technology (2017-2030)
    • 15.2.1. Molecular assay market revenue, by type (2017-2030)
    • 15.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 15.3. Market Revenue, by Offering (2017-2030)
  • 15.4. Market Revenue, by Transplant Type (2017-2030)
    • 15.4.1. Solid organ market revenue, by type (2017-2030)
  • 15.5. Market Revenue, by Application (2017-2030)
  • 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Technology (2017-2030)
    • 16.2.1. Molecular assay market revenue, by type (2017-2030)
    • 16.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 16.3. Market Revenue, by Offering (2017-2030)
  • 16.4. Market Revenue, by Transplant Type (2017-2030)
    • 16.4.1. Solid organ market revenue, by type (2017-2030)
  • 16.5. Market Revenue, by Application (2017-2030)
  • 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Technology (2017-2030)
    • 17.2.1. Molecular assay market revenue, by type (2017-2030)
    • 17.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 17.3. Market Revenue, by Offering (2017-2030)
  • 17.4. Market Revenue, by Transplant Type (2017-2030)
    • 17.4.1. Solid organ market revenue, by type (2017-2030)
  • 17.5. Market Revenue, by Application (2017-2030)
  • 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Technology (2017-2030)
    • 18.2.1. Molecular assay market revenue, by type (2017-2030)
    • 18.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 18.3. Market Revenue, by Offering (2017-2030)
  • 18.4. Market Revenue, by Transplant Type (2017-2030)
    • 18.4.1. Solid organ market revenue, by type (2017-2030)
  • 18.5. Market Revenue, by Application (2017-2030)
  • 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Technology (2017-2030)
    • 19.2.1. Molecular assay market revenue, by type (2017-2030)
    • 19.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 19.3. Market Revenue, by Offering (2017-2030)
  • 19.4. Market Revenue, by Transplant Type (2017-2030)
    • 19.4.1. Solid organ market revenue, by type (2017-2030)
  • 19.5. Market Revenue, by Application (2017-2030)
  • 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Technology (2017-2030)
    • 20.2.1. Molecular assay market revenue, by type (2017-2030)
    • 20.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 20.3. Market Revenue, by Offering (2017-2030)
  • 20.4. Market Revenue, by Transplant Type (2017-2030)
    • 20.4.1. Solid organ market revenue, by type (2017-2030)
  • 20.5. Market Revenue, by Application (2017-2030)
  • 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Technology (2017-2030)
    • 21.2.1. Molecular assay market revenue, by type (2017-2030)
    • 21.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 21.3. Market Revenue, by Offering (2017-2030)
  • 21.4. Market Revenue, by Transplant Type (2017-2030)
    • 21.4.1. Solid organ market revenue, by type (2017-2030)
  • 21.5. Market Revenue, by Application (2017-2030)
  • 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Technology (2017-2030)
    • 22.2.1. Molecular assay market revenue, by type (2017-2030)
    • 22.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 22.3. Market Revenue, by Offering (2017-2030)
  • 22.4. Market Revenue, by Transplant Type (2017-2030)
    • 22.4.1. Solid organ market revenue, by type (2017-2030)
  • 22.5. Market Revenue, by Application (2017-2030)
  • 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Technology (2017-2030)
    • 23.2.1. Molecular assay market revenue, by type (2017-2030)
    • 23.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 23.3. Market Revenue, by Offering (2017-2030)
  • 23.4. Market Revenue, by Transplant Type (2017-2030)
    • 23.4.1. Solid organ market revenue, by type (2017-2030)
  • 23.5. Market Revenue, by Application (2017-2030)
  • 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Technology (2017-2030)
    • 24.2.1. Molecular assay market revenue, by type (2017-2030)
    • 24.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 24.3. Market Revenue, by Offering (2017-2030)
  • 24.4. Market Revenue, by Transplant Type (2017-2030)
    • 24.4.1. Solid organ market revenue, by type (2017-2030)
  • 24.5. Market Revenue, by Application (2017-2030)
  • 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Technology (2017-2030)
    • 25.2.1. Molecular assay market revenue, by type (2017-2030)
    • 25.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 25.3. Market Revenue, by Offering (2017-2030)
  • 25.4. Market Revenue, by Transplant Type (2017-2030)
    • 25.4.1. Solid organ market revenue, by type (2017-2030)
  • 25.5. Market Revenue, by Application (2017-2030)
  • 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Technology (2017-2030)
    • 26.2.1. Molecular assay market revenue, by type (2017-2030)
    • 26.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 26.3. Market Revenue, by Offering (2017-2030)
  • 26.4. Market Revenue, by Transplant Type (2017-2030)
    • 26.4.1. Solid organ market revenue, by type (2017-2030)
  • 26.5. Market Revenue, by Application (2017-2030)
  • 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Technology (2017-2030)
    • 27.2.1. Molecular assay market revenue, by type (2017-2030)
    • 27.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 27.3. Market Revenue, by Offering (2017-2030)
  • 27.4. Market Revenue, by Transplant Type (2017-2030)
    • 27.4.1. Solid organ market revenue, by type (2017-2030)
  • 27.5. Market Revenue, by Application (2017-2030)
  • 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Technology (2017-2030)
    • 28.2.1. Molecular assay market revenue, by type (2017-2030)
    • 28.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 28.3. Market Revenue, by Offering (2017-2030)
  • 28.4. Market Revenue, by Transplant Type (2017-2030)
    • 28.4.1. Solid organ market revenue, by type (2017-2030)
  • 28.5. Market Revenue, by Application (2017-2030)
  • 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. bioMerieux S.A.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. Thermo Fisher Scientific Inc.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Bio-Rad Laboratories Inc.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Abbott Laboratories
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. Hologic Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. F. Hoffmann-La Roche Ltd.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Laboratory Corporation of America Holdings
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. BAG Diagnostics GmbH
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Illumina Inc.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports